Business Description
Immutep Ltd
NAICS : 325412
SIC : 2834
ISIN : US45257L1089
Share Class Description:
IMMP: ADRDescription
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 114.1 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 10.4 | |||||
| 3-Year EPS without NRI Growth Rate | 2.6 | |||||
| 3-Year FCF Growth Rate | -1.1 | |||||
| 3-Year Book Growth Rate | 10.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.49 | |||||
| 9-Day RSI | 28.62 | |||||
| 14-Day RSI | 31.16 | |||||
| 6-1 Month Momentum % | -27.3 | |||||
| 12-1 Month Momentum % | 7.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 18.25 | |||||
| Quick Ratio | 18.25 | |||||
| Cash Ratio | 17.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23.7 | |||||
| Shareholder Yield % | -0.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year ROIIC % | 450.75 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | N/A |
N/A
|
N/A
| |||
| Forward PE Ratio | 5.92 | |||||
| PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
| PB Ratio | 2.14 | |||||
| Price-to-Tangible-Book | 2.14 | |||||
| EV-to-EBIT | -5.07 | |||||
| EV-to-Forward-EBIT | -4.86 | |||||
| EV-to-EBITDA | -5.07 | |||||
| EV-to-Forward-EBITDA | -5.08 | |||||
| EV-to-Forward-Revenue | 23.93 | |||||
| EV-to-FCF | -7.26 | |||||
| Price-to-Net-Current-Asset-Value | 2.3 | |||||
| Price-to-Net-Cash | 2.3 | |||||
| Earnings Yield (Greenblatt) % | -19.72 | |||||
| FCF Yield % | -7.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMMP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immutep Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0 | ||
| Beta | 1.94 | ||
| Volatility % | 58.25 | ||
| 14-Day RSI | 31.16 | ||
| 14-Day ATR ($) | 0.092206 | ||
| 20-Day SMA ($) | 1.95125 | ||
| 12-1 Month Momentum % | 7.89 | ||
| 52-Week Range ($) | 1.58 - 3.335 | ||
| Shares Outstanding (Mil) | 145.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immutep Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immutep Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Immutep Ltd Frequently Asked Questions
What is Immutep Ltd(IMMP)'s stock price today?
The current price of IMMP is $1.82. The 52 week high of IMMP is $3.34 and 52 week low is $1.58.
When is next earnings date of Immutep Ltd(IMMP)?
The next earnings date of Immutep Ltd(IMMP) is 2025-02-27 Est..
Does Immutep Ltd(IMMP) pay dividends? If so, how much?
Immutep Ltd(IMMP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers